Join Us

We are 221,759 members in 83 forums discussing 162,137 topics.

Help with Abbreviations

Topic: Combo therapy -- outcomes in treatment-resistant liver ca

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Nov 30, 2020 10:32PM

wallycat wrote:

https://www.sciencedaily.com/releases/2020/11/2011...


Summary:
A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to 'reprogram' the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone.


Dx 4/07 1 month before turning 50; ILC 1.8cm, ER+/PR+, HER2 neg., Stage 1, Grade 2, 0/5 nodes. Onco score 20, Bilateral Mast., tamoxifen 3-1/2 years, arimidex-completed 4/20/2012
Log in to post a reply